SCHEMBL4099339

SCHEMBL4099339

N#CN=C1Nc2ccc(-c3cccc(Cl)c3)cc2C12CCCCC2

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PGR P06401 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105191 1.00 PGR (0.63) PGR
SCHEMBL3422468 0.78 PGR (0.70) PGR
SCHEMBL4534292 0.78 PGR (0.70) PGR
SCHEMBL6013866 0.78 PGR (1.00) PGR
SCHEMBL4101423 0.78 PGR (1.00) PGR
SCHEMBL4099263 0.77 PGR (0.71) PGR
SCHEMBL4099266 0.77 PGR (0.71) PGR
SCHEMBL4094429 0.76 PGR (0.71) PGR
SCHEMBL4094432 0.76 PGR (0.71) PGR
SCHEMBL4104517 0.76 PDE7A (0.40) PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220558-A1 Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives WYETH LLC (US) 2012-08-30 US claimed
US-20090099223-A1 METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES WYETH (US) 2009-04-16 US claimed
US-7115649-B2 Methods of treating skin disorders using thio-oxindole derivatives WYETH (US) 2006-10-03 US claimed
US-6946454-B2 Thio-oxindole derivatives WYETH (US) 2005-09-20 US claimed
US-20050171186-A1 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic WYETH (US) 2005-08-04 US claimed
US-20040006122-A1 Methods of treating skin disorders using thio-oxindole derivatives WYETH 2004-01-08 US claimed
US-20040002535-A1 Methods of treating hormone-related conditions using thio-oxindole derivatives WYETH (US) 2004-01-01 US claimed
US-20020169198-A1 Thio-oxindole derivatives WYETH (US) 2002-11-14 US claimed
US-6355648-B1 COMPOUNDS AS CONTRACEPTIVES AND PROGESTERONE ANTAGONIST AMERICAN HOME PRODUCTS CORPORATION 2002-03-12 US claimed
US-20120220558-A1 Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives WYETH LLC (US) 2012-08-30 US disclosed
US-8242098-B2 Methods of treating hormone-related conditions using thio-oxindole derivatives WYETH LLC (US) 2012-08-14 US disclosed
US-20090099223-A1 METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES WYETH (US) 2009-04-16 US disclosed
US-7488734-B2 Methods of treating hormone-related conditions using thio-oxindole derivatives WYETH (US) 2009-02-10 US disclosed
US-7115649-B2 Methods of treating skin disorders using thio-oxindole derivatives WYETH (US) 2006-10-03 US disclosed
EP-1531806-A4 USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS WYETH CORP (US) 2005-09-21 EP disclosed
EP-1531806-A2 USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS Wyeth (US) 2005-05-25 EP disclosed
US-20040006122-A1 Methods of treating skin disorders using thio-oxindole derivatives WYETH 2004-01-08 US disclosed
US-20040002535-A1 Methods of treating hormone-related conditions using thio-oxindole derivatives WYETH (US) 2004-01-01 US disclosed
WO-2004000225-A2 USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS WYETH (US) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002535-A1 Methods of treating hormone-related conditions using thio-oxindole derivatives GPER1, OXTR, SHBG PGR 44/4885
US-20040006122-A1 Methods of treating skin disorders using thio-oxindole derivatives SRD5A1, SRD5A2, OXER1 PGR 1297/4885
US-20120220558-A1 Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives OXTR, GNRHR, SHBG PGR 23/4885
US-20050171186-A1 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic PGR, ESR1, PGRMC1 PGR 1/4885
US-20020169198-A1 Thio-oxindole derivatives GPER1, PGR, ESR1 PGR 2/4885
US-20090099223-A1 METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES OXTR, GNRHR, SHBG PGR 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.